Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
4.050
-0.200 (-4.71%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.
It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Zentalis Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Apr 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Julie Eastland |
Contact Details
Address: 10275 Science Center Dr., Suite 200 San Diego, California 92121 United States | |
| Phone | 858 263 4333 |
| Website | zentalis.com |
Stock Details
| Ticker Symbol | ZNTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001725160 |
| CUSIP Number | 98943L107 |
| ISIN Number | US98943L1070 |
| Employer ID | 82-3607803 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Julie M. Eastland M.B.A. | Chief Executive Officer, President and Director |
| Vincent A. Vultaggio | SVice President of Finance and Principal Accounting Officer |
| Robert J. DiVasto P.E. | Chief Technical Officer |
| James B. Bucher J.D. | Chief Legal Officer and Corporate Secretary |
| Wendy Chang | Chief People Officer |
| Dr. Ingmar Bruns M.D., Ph.D. | Chief Medical Officer |
| Haibo Wang | Chief Business Officer |
| Rajesh Israni | Executive Vice President of Regulatory Affairs and Medical Writing |
| Henry Gu | Senior Vice President and Head of Intellectual Property |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2026 | 8-K | Current Report |
| Apr 9, 2026 | 8-K | Current Report |
| Mar 26, 2026 | 10-K | Annual Report |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 3, 2026 | SCHEDULE 13G | Filing |
| Jan 9, 2026 | 8-K | Current Report |
| Jan 5, 2026 | SCHEDULE 13G/A | Filing |
| Jan 2, 2026 | SCHEDULE 13D/A | Filing |
| Dec 30, 2025 | SCHEDULE 13G | Filing |
| Dec 15, 2025 | SCHEDULE 13D/A | Filing |